Navigation Links
Moderate doses of radiation therapy to unaffected breast may prevent second breast cancers

NEW YORK, NY (January 23, 2014) Survivors of breast cancer have a one in six chance of developing breast cancer in the other breast. But a study conducted in mice suggests that survivors can dramatically reduce that risk through treatment with moderate doses of radiation to the unaffected breast at the same time that they receive radiation therapy to their affected breast. The treatment, if it works as well in humans as in mice, could prevent tens of thousands of second breast cancers. The study, conducted by researchers at Columbia University Medical Center (CUMC), was published on December 20 in the online journal PLOS ONE.

"Over the past decades, we've had great success in treating breast cancer, and the 15-year survival rate is now 77 percent," said study leader David J. Brenner, PhD, director of CUMC's Center for Radiological Research and the Higgins Professor of Radiation Biophysics. "Unfortunately, breast cancer survivors have a several times higher risk of developing cancer in their other breast, compared with healthy women of the same age."

"While drugs such as tamoxifen and aromatase inhibitors can reduce the risk somewhat, at least for women with estrogen receptor-positive tumors, the long-term risks of a second breast cancer in the unaffected breast remain high. Because of these risks, approximately 10 to 20 percent of breast cancer survivors in the U.S. undergo prophylactic mastectomy of their other breast," said Dr. Brenner.

The idea for prophylactic mammary irradiation (PMI) of the unaffected breast stems from an earlier study of standard whole-breast irradiation after lumpectomy. In that study, Dr. Brenner found that radiation is highly effective at killing premalignant cells, not only in the quadrant of the breast where the primary tumor was located, but also in the other three quadrants, where premalignant cells are generally considered to be unrelated to the primary tumor. "So, we thought, why can't we treat the other breast with a moderate dose of radiation and kill any premalignant cells that could lead to second cancers?" said Dr. Brenner.

The critical question was whether treating the breast with a moderate dose of radiation would indeed lower the overall risk of a second cancer. "We know that there will be a balance between radiation killing premalignant cells and radiation producing premalignant cells, but it seemed that using the right radiation dose would put the balance strongly toward lowering the cancer risk," Dr. Brenner said.

The current study tested this hypothesis by performing PMI on transgenic mice that have a high risk of developing breast cancer, simulating the unaffected breast of a breast cancer survivor. Lead shields were positioned so that one side of each mouse was shielded from the radiation. As predicted, a moderate dose of radiation reduced the breast cancer risk in the treated side by a factor of about 3.

The researchers are now planning to test PMI in a clinical trial.

If PMI proves to be successful in patients, it could be used as an adjunct to tamoxifen or aromatase inhibitors for women with estrogen receptor-positive tumors and as a standalone therapy for those with estrogen-receptor negative tumors, who do not benefit from drug therapy. In either case, PMI could be performed concurrently with radiotherapy of the affected breast.

PMI could have a substantial clinical impact. At present, there are more than 2.6 million breast cancer survivors in the U.S., according to the American Cancer Society. "About 160,000 of these women are likely to develop cancer in their other breast," said Dr. Brenner. "If PMI does, in fact, reduce the incidence of cancer by three-fold, as suggested by our results, about 100,000 cases of breast cancer could be prevented."

"Whether PMI would work for women with BRACA1 or BRACA2 mutations, which greatly increase one's risk for breast and/or ovarian cancer, is another story," said Dr. Brenner. "We don't know that. Our next mouse study will look at the effects of PMI in BRACA1 mice."

The paper is titled, "Potential Reduction of Contralateral Second Breast-Cancer Risks by Prophylactic Mammary Irradiation: Validation in a Breast-Cancer-Prone Mouse Model." The other contributors are Igor Shuryak, Lubomir B. Smilenov, and Norman J. Kleiman, all at CUMC.


Contact: Karin Eskenazi
Columbia University Medical Center

Related biology news :

1. Study: Moderate alcohol consumption boosts bodys immune system
2. New study suggests coral reefs may be able to adapt to moderate climate change
3. Moderate exercise not only treats, but prevents depression
4. Latest research suggests moderate coffee consumption is not associated with increased CVD risk
5. Moderate exercising encourages a healthier lifestyle
6. UEA research shows moderate exercise could be good for your tendons
7. Experts find epigenetic changes moderate reality distortion in schizophrenia patients
8. Cells must use their brakes moderately for effective speed control
9. CNBC Senior Analyst Ron Insana Moderates Discussion On Biotech Seeds At The Food Dialogues(SM): Chicago
10. Researchers issue forecast for moderate New England red tide in 2013
11. Moderate drinking decreases number of new brain cells
Post Your Comments:
Related Image:
Moderate doses of radiation therapy to unaffected breast may prevent second breast cancers
(Date:11/12/2015)... -- A golden retriever that stayed healthy despite having the ... a new lead for treating this muscle-wasting disorder, report ... MIT and Harvard and the University of São Paolo ... Cell, pinpoints a protective gene that boosts muscle ... Boston Children,s lab of Lou Kunkel , PhD, ...
(Date:11/10/2015)... , Nov. 10, 2015 ... behavioral biometrics that helps to identify and verify ... Signature is considered as the secure and accurate ... identification of a particular individual because each individual,s ... accurate results especially when dynamic signature of an ...
(Date:10/29/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that it has ... as one of only three finalists for a ... and Growing" category. The Tekne Awards honor Minnesota ... technology innovation and leadership. iMedNet™ eClinical ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna ... announced today that the remaining 11,000 post-share consolidation ... Purchase Warrants (the "Series B Warrants") subject to ... exercised on November 23, 2015, which will result ... After giving effect to the issuance of such ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... are paramount. Insertion points for in-line sensors can represent a weak spot where ... InTrac 781/784 series of retractable sensor housings , which are designed to tolerate ...
(Date:11/24/2015)... Vancouver, BC (PRWEB) , ... November 24, 2015 ... ... to our customer, OrthoAccel® Technologies, Inc., on being named to Deloitte's 2015 Technology ... Creation Technologies’ Texas facility, OrthoAccel manufactures AcceleDent®, a FDA-cleared, Class II medical device ...
(Date:11/24/2015)... 24, 2015 Capricor Therapeutics, Inc. ... the discovery, development and commercialization of first-in-class therapeutics, today ... Officer, is scheduled to present at the 2015 Piper ... a.m. EST, at The Lotte New York Palace Hotel ... . --> . ...
Breaking Biology Technology: